Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata, but the filing text identifies OncoGenex) for the reporting period of September 22, 2010. The report discloses a material event under Item 8.01 regarding the publication of clinical trial data.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event rather than financial performance.
Material Changes
On September 22, 2010, the company issued a press release announcing that the Journal of Clinical Oncology published data from a randomized Phase 2 trial for the company's drug candidate, Custirsen. This publication is the primary material change reported in this document.
Guidance, Outlook, and Risks
The filing incorporates a press release by reference (Exhibit 99.1) but does not contain specific management commentary, financial guidance, or a detailed risk assessment within the body of the 8-K text. The document serves to notify investors of the clinical data publication.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for specific details on the Custirsen Phase 2 trial results.
- Confirm the company name discrepancy between the metadata ("ACHIEVE LIFE SCIENCES, INC.") and the filing header ("ONCOGENEX PHARMACEUTICALS, INC.").
- Review the Journal of Clinical Oncology publication referenced to understand the clinical significance of the data.